Fig. 6From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinomaThe imaging (A) and pathological microenvironmental (B) changes of patient No.6 underwent immunotherapy and stereotactic ablative radiotherapyBack to article page